BioRadar®
Early Detection
Identify pathogens + resistance genes before symptoms escalate
Precision Action
Guide targeted therapy with AI-interpreted treatment roadmaps
Dynamic Monitoring
Track treatment response in real time to prevent relapse
Outbreak Containment
Map hospital environments to stop silent transmission
Future-Proofing
Detect emerging threats (e.g., Disease X) for proactive defence
A paradigm-shifting molecular diagnostic solution.
Combining proprietary EFAD® Lab-on-Chip, microfluidics, AI and full-automation engineering. Not only meets WHO REASSURED* criteria for diagnostic instruments, but also delivers personalized diagnosis and treatment for severe pneumonia patients.
Ultra-Multiplex Detection
Up to 441 Pathogens and/or Genes
Up to 441 Pathogens and/or Genes
Simultaneous detection of 95% of pneumonia-relevant pathogens and antimicrobial resistance (AMR) genes
Full Automation
Single-Use Cartridge Design
Cost-Optimized Diagnostics Aligned with Clinical Priorities
Cost-Optimized Diagnostics Aligned with Clinical Priorities
Quantification
Quantify pathogens to monitor treatment response
Enable precision therapy and guide clinical care
Enable precision therapy and guide clinical care
High Specificity & Sensitivity
EFAD® Lab-on-Chip provides accurate infection identification. Avoiding false results, so treatments can be adjusted with confidence
<2h Sample-to-Result Workflow
Enables True Point-of-Care Diagnosis
Why Experts Trust BioRadar®
“It’s a unique system. You get a readout much faster than with other technologies. It’s easy to say you want to make a biochip like this,” Zhuang says. “It’s another thing to do it. Albert is focused and stubborn, and he found a way.”
Prof. Zhengping Zhuang
Clinical pathologist, U.S. NIH
“It’s no surprise that Hai Kang Life got there first,“ says Bernard Roizman, a virologist at the University of Chicago in Illinois. Many diagnostics companies prefer to sell large, complicated, and expensive machines, he says. EFAD chip readers are the size of a microwave oven. “Attach it to a power supply, and it’s a lab on a chip on wheels,” Roizman says. “It could identify a new infectious agent in time to curtail its spread.”
Prof. Bernard Roizman
Virologist, University of Chicago in Illinois
Why Partner or Invest BioRadar®
First-in-ClassDisruptive technologyLive-Saving
Targeting critical care settingsDeploy in emergency departments and ICUs to accelerate pneumonia diagnosis and guide urgent treatment decisions
Timely detectionDeploy AI-powered diagnostics to reduce misdiagnosis and accelerate life-saving interventions
Scale globallyIntegrate BioRadar® into hospitals, primary care clinics, and public health initiatives – especially in regions with limited diagnostic infrastructure
English 
Chinese